Binder Blinders-Niacin of Omission?

American Journal of Kidney Diseases

Volumn 55, Issue 4, 2010, Pages 628-630

  Bostom, Andrew G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CALCIUM ACETATE; FIBROBLAST GROWTH FACTOR 23; LANTHANUM; NICERITROL; NICOTINAMIDE; NICOTINIC ACID; SEVELAMER; SODIUM PHOSPHATE COTRANSPORTER;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; EDITORIAL; HEMODIALYSIS PATIENT; HUMAN; HYPOPHOSPHATEMIA; KIDNEY FAILURE; LOW DRUG DOSE; MORTALITY; NONHUMAN; PHOSPHATE BLOOD LEVEL; SMALL INTESTINE ABSORPTION;

ANIMALS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERPHOSPHATEMIA; KIDNEY DISEASES; NIACIN; NICERITROL;

EID: 77949567521     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.12.015     Document Type: Editorial

References (20)

1. Nash O. Portrait of the artist as prematurely old man. In: Smith L.N. (Ed). The Best of Ogden Nash. 3rd ed. (2007), Ivan R. Dee, Chicago, IL 366
2. Block G.A., Persky M.S., Ketteler M., et al. A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodial Int 13 3 (2009) 260-262
3. Isakova T., Gutiérrez O.M., and Wolf M. A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int 76 7 (2009) 705-716
4. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113 (2009) S121-S130 doi:10.1038/ki.2009.197
5. Shimoda K., Akiba T., Matsushima T., Rai T., Abe K., and Hoshino M. Niceritrol decreases serum phosphate levels in chronic hemodialysis patients. Nippon Jinzo Gakkai Shi 40 1 (1998) 1-7
6. Sampathkumar K., Sooraj Y., Mahaldar A.R., and Ramakrishnan M. Comparative efficiency of low dose nicotinic acid and lanthanum in lowering the phosphorus levels in hemodialysis patients [S-PO-0327]. World Congress of Nephrology. Rio de Janeiro, Brazil (April 21-25, 2007)
7. Sampathkumar K. Niacin and analogs for phosphate control in dialysis-perspective from a developing country. Int Urol Nephrol 41 4 (2009) 813-918
8. Knopp R.H., Alagona P., Davidson M., et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 47 9 (1998) 1097-1104
9. Capuzzi D.M., Guyton J.R., Morgan J.M., et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 82 12A (1998) 74U-81U
10. Guyton J.R., Blazing M.A., Hagar J., et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med 160 8 (2000) 1177-1184
11. Maccubbin D., Bays H.E., Olson G., et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolemia or mixed dyslipidaemia. Int J Clin Pract 62 12 (2008) 1959-1970
12. Kuboyama N., Watanabe Y., Yamaguchi M., Sato K., Suzuki T., and Akiba T. Effects of niceritrol on faecal and urinary phosphate excretion in normal rats. Nephrol Dial Transplant 14 3 (1999) 610-614
13. Katai K., Tanaka H., Tatsumi S., et al. Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 14 5 (1999) 1195-1201
14. Eto N., Miyata Y., Ohno H., and Yamashita T. Nicotinamide prevents the development of hyperphosphatemia by suppressing the intestinal sodium dependent phosphate transporter in rats with adenine induced renal failure. Nephrol Dial Transplant 20 7 (2005) 1378-1384
15. Sabbagh Y., O'Brien S.P., Song W., et al. Intestinal Npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 20 11 (2009) 2348-2358
16. Shahapuni I., Rahmouni K., Arrar B., Harbouche L., Esper N., and Fournier A. Greater cost effectiveness of nicotinamide compared with that of sevelamer for controlling hyperphosphatemia in dialysis patients [S-PO-0311]. World Congress of Nephrology. Rio de Janeiro, Brazil (April 22, 2007)
17. Chiu Y.W., Teitelbaum I., Misra M., de Leon E.M., Adzize T., and Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 4 6 (2009) 1089-1096
18. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8 6 (1986) 1245-1255
19. Canner P.L., Furberg C.D., Terrin M.L., and McGovern M.E. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 95 2 (2005) 254-257
20. Coca S.G., Krumholz H.M., Garg A.X., and Parikh C.R. Under-representation of renal disease in randomized controlled trials of cardiovascular disease. JAMA 296 11 (2006) 1377-1384